BATTLEFIELD WOUND INFECTION PREVENTION AND TREATMENT (BWI P&T): BARRIER COMBINATION PRODUCT DEVELOPMENT

The Defense Health Agency (DHA) Operational Medical Systems – Warfighter Protection and Acute Care office is conducting market research for a “Barrier Combination” product to prevent and treat bacterial and fungal infections in battlefield wounds (BWI P&T). The product must satisfy the Minimum Essential Characteristics listed in Attachment 3 and achieve at least Technology Readiness Level 4 (see Attachment 1). Responses should demonstrate the respondent’s ability to meet the minimum (and, if possible, desired) characteristics, provide required company and product information (Attachment 2), and include a one‑page cover sheet with contact details. Submissions must be in Microsoft Word or searchable PDF, formatted in Arial 12‑point, single‑spaced, 8.5 × 11 in., 1‑inch margins, and emailed to Jeanette M. Collins (jeanette.m.collins4.civ@health.mil) by 2:00 p.m. Eastern on 20 January 2026. The DHA encourages participation from all qualified firms, especially small businesses, and requires any proprietary, classified, confidential, or sensitive data to be clearly marked. This RFI is for information gathering only; a future solicitation may be issued based on the responses.

Notice ID

0f7bf84a247c425b970819fb5a0f4b60

Solicitation Number

HT9427-26-RFI-BWI-PT

NAICS Code

N/A

Classification Code

N/A